Department of Urology, San Francisco Veterans Affairs Medical Center and University of California at San Francisco, San Francisco, CA 94121, USA.
Int J Impot Res. 2009 Nov-Dec;21(6):348-55. doi: 10.1038/ijir.2009.28. Epub 2009 Jun 25.
We hypothesized that the administration of the superoxide dismutase (SOD) mimetic Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) may reverse diabetes-induced erectile dysfunction. To test this hypothesis, reactive oxygen species-related genes (SOD1, SOD2, GP x 1, CAT, NOS2, NOS3) were tested, erectile functional studies and immunohistochemical analysis were carried out in diabetic rats treated with or without Tempol. Thirty Sprague-Dawley (3-4 months old) rats were divided into three groups (n=10 each), 20 with diabetes (diabetic control and Tempol treatment) and 10 healthy controls. At 12 weeks after the induction of diabetes by streptozotocin and Tempol treatment, all groups underwent in vivo cavernous nerve stimulation. Rat crura were harvested and the expression of antioxidative defense enzymes were examined by semi-quantitative reverse transcriptase PCR (RT-PCR). To confirm the RT-PCR results, we carried out immunohistochemistry (IHC) for catalase (CAT) and iNOS (NOS2). Nitration of tyrosine groups in proteins was also examined by IHC. Mean intracavernous pressure in the diabetic group was significantly lower than in the healthy controls (P <0.001) and was reversed by Tempol treatment (P <0.0108). NOS2 protein expression was significantly increased in diabetic animals compared with healthy controls and Tempol restored NOS2 protein level. Nitrotyrosine was also higher in diabetic animals and although Tempol treatment decreased its formation, it remained higher than that found in healthy controls. This study suggests that Tempol treatment increased erectile function through modulating oxidative stress-related genes in diabetic rats. This is the first report about the relationship between diabetes-induced erectile dysfunction and oxidative stress, and antioxidative therapy using the superoxide dismutase mimetic, Tempol, to restore erectile function.
我们假设,超氧化物歧化酶(SOD)类似物 Tempol(4-羟基-2,2,6,6-四甲基哌啶 1-氧自由基)的给药可能逆转糖尿病引起的勃起功能障碍。为了验证这一假设,我们在接受或未接受 Tempol 治疗的糖尿病大鼠中测试了与活性氧相关的基因(SOD1、SOD2、GPx1、CAT、NOS2、NOS3),并进行了勃起功能研究和免疫组织化学分析。30 只 Sprague-Dawley(3-4 个月大)大鼠分为三组(每组 10 只),20 只为糖尿病(糖尿病对照组和 Tempol 治疗组),10 只为健康对照组。在链脲佐菌素诱导糖尿病和 Tempol 治疗 12 周后,所有组均进行了体内海绵体神经刺激。采集大鼠阴茎,通过半定量逆转录聚合酶链反应(RT-PCR)检测抗氧化防御酶的表达。为了证实 RT-PCR 结果,我们对过氧化氢酶(CAT)和诱导型一氧化氮合酶(NOS2)进行了免疫组织化学(IHC)检测。我们还通过 IHC 检测了蛋白质中酪氨酸基团的硝化。糖尿病组的平均海绵体内压明显低于健康对照组(P<0.001),并通过 Tempol 治疗得到逆转(P<0.0108)。与健康对照组相比,糖尿病动物的 NOS2 蛋白表达显著增加,Tempol 恢复了 NOS2 蛋白水平。糖尿病动物的硝基酪氨酸水平也较高,尽管 Tempol 治疗减少了其形成,但仍高于健康对照组。本研究表明,Tempol 治疗通过调节糖尿病大鼠氧化应激相关基因增加了勃起功能。这是首次报道糖尿病引起的勃起功能障碍与氧化应激之间的关系,以及使用超氧化物歧化酶类似物 Tempol 进行抗氧化治疗以恢复勃起功能。